- Home
- IMNN vs NERV Comparison
IMNN vs NERV Comparison
Compare IMNN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- NERV
- Stock Information
- Founded
- IMNN 1982
- NERV 2007
- Country
- IMNN United States
- NERV United States
- Employees
- IMNN N/A
- NERV N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- NERV Health Care
- Exchange
- IMNN Nasdaq
- NERV Nasdaq
- Market Cap
- IMNN 12.1M
- NERV 12.0M
- IPO Year
- IMNN 1985
- NERV 2014
- Fundamental
- Price
- IMNN $7.61
- NERV $1.91
- Analyst Decision
- IMNN Buy
- NERV Hold
- Analyst Count
- IMNN 2
- NERV 1
- Target Price
- IMNN $210.00
- NERV $5.00
- AVG Volume (30 Days)
- IMNN 405.2K
- NERV 21.2K
- Earning Date
- IMNN 08-05-2025
- NERV 08-05-2025
- Dividend Yield
- IMNN N/A
- NERV N/A
- EPS Growth
- IMNN N/A
- NERV N/A
- EPS
- IMNN N/A
- NERV 0.83
- Revenue
- IMNN N/A
- NERV N/A
- Revenue This Year
- IMNN N/A
- NERV N/A
- Revenue Next Year
- IMNN N/A
- NERV N/A
- P/E Ratio
- IMNN N/A
- NERV $2.36
- Revenue Growth
- IMNN N/A
- NERV N/A
- 52 Week Low
- IMNN $5.55
- NERV $1.15
- 52 Week High
- IMNN $54.75
- NERV $3.30
- Technical
- Relative Strength Index (RSI)
- IMNN 38.74
- NERV 51.36
- Support Level
- IMNN $6.51
- NERV $1.94
- Resistance Level
- IMNN $8.10
- NERV $2.32
- Average True Range (ATR)
- IMNN 1.32
- NERV 0.16
- MACD
- IMNN 0.20
- NERV 0.00
- Stochastic Oscillator
- IMNN 20.04
- NERV 41.73
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.